Why Are Novavax Shares Trading Lower Today?
Why Are Novavax Shares Trading Lower Today?
Novavax Inc. (NASDAQ:NVAX) shares are on watch Thursday. Here's a recap of recent events.
周四，Novavax Inc.（纳斯达克股票代码：NVAX）的股票值得关注。以下是近期事件的回顾。
Key Developments:
主要进展：
- Short Interest: Novavax's short interest has fallen, signaling that fewer investors are betting against the stock. It would take about 3.09 days to cover all short positions based on average trading volumes.
- FDA Approval: Novavax's updated COVID-19 vaccine has been approved and will be available at thousands of locations across the U.S., including retail pharmacies and grocers. This approval strengthens Novavax's position in the market as it continues to offer a unique protein-based vaccine alternative.
- Revenue Guidance: In August, Novavax lowered its 2024 revenue guidance to between $700 million and $800 million, significantly below earlier projections.
- 空头利息：Novavax的空头利率有所下降，这表明押注该股的投资者越来越少。根据平均交易量，填补所有空头头寸大约需要3.09天。
- 美国食品药品管理局批准：Novavax更新后的 COVID-19 疫苗已获得批准，将在美国数千个地点上市，包括零售药房和杂货店。这一批准巩固了Novavax在市场上的地位，因为它将继续提供独特的基于蛋白质的疫苗替代品。
- 收入指导：8月，Novavax将其2024年的收入预期下调至7亿至8亿美元之间，大大低于先前的预期。
In comparison, Moderna Inc. (NASDAQ:MRNA) also shared updates during its R&D day, projecting 2025 revenues of $2.5 billion to $3.5 billion, below the consensus of $3.74 billion. The company is cutting its R&D budget by $1.1 billion by 2027 and focusing on ten prioritized products. Despite lower-than-expected revenue forecasts, Moderna remains confident in its long-term growth and cash reserves.
相比之下，摩德纳公司（纳斯达克股票代码：MRNA）也在研发日分享了最新情况，预计2025年收入为25亿美元至35亿美元，低于市场预期的37.4亿美元。该公司将在2027年之前将其研发预算削减11亿美元，并将重点放在十种优先产品上。尽管收入预测低于预期，但Moderna对其长期增长和现金储备仍然充满信心。
NVAX Price Action: Novavax shares were down by 2.48% at $11.99 according to Benzinga Pro.
NVAX价格走势：根据Benzinga Pro的数据，Novavax股价下跌2.48％，至11.99美元。
- Jim Cramer Sees Opportunity In Micron Stock As Death Cross, Earnings Approach
- 吉姆·克莱默认为，随着死亡的临近，美光股票的机会即将来临
Photo via Shutterstock.
照片来自 Shutterstock。